Session » Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases

Date: Tuesday, October 23, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2152

A Comparison of the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics Classification (SLICC) Criteria to Detect Patients with Systemic Lupus Erythematosus (SLE) in Electronic Health Record (EHR) Data

9:00AM-11:00AM: Abstract Number: 2146

A Meta-Analysis of the Prevalence and Risk Factors for Retinal Toxicity in Rheumatologic Patients on Hydroxychloroquine Therapy

9:00AM-11:00AM: Abstract Number: 2132

All-Cause Mortality, Hospitalization, and Systemic Lupus Erythematosus (SLE) Related Complications in 2011-2015 Medicare Beneficiaries with SLE

9:00AM-11:00AM: Abstract Number: 2149

Assessing the Prevalence of Localized Scleroderma in Childhood Using Dministrative Claims Data from the United States

9:00AM-11:00AM: Abstract Number: 2140

Association of Hydroxychloroquine Use and Incident Atrial Fibrillation in Rheumatoid Arthritis: A Retrospective Study

9:00AM-11:00AM: Abstract Number: 2150

Association of Poverty Income Ratio with Physical Functioning in a Cohort of Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2147

Associations between Current Cigarette Smoking and SLE-Related Cytokine and Chemokine Biomarkers Among U.S. Female Nurses without SLE

9:00AM-11:00AM: Abstract Number: 2159

Autoimmune Diseases in Catalonia: A Population Based Study Using a Public Big Data Program

9:00AM-11:00AM: Abstract Number: 2154

Biosimilar Infliximab Treated-Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in France: Characteristics and Clinical Outcomes

9:00AM-11:00AM: Abstract Number: 2158

Clinical Significance of Anti-Ro52 Antibody in Chinese Patients with Connective Tissue Diseases: A Single-Center Experience

9:00AM-11:00AM: Abstract Number: 2133

Comparative Disease Burden of Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Data from the Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries

9:00AM-11:00AM: Abstract Number: 2141

Development of a Pediatric Glucocorticoid Toxicity Index

9:00AM-11:00AM: Abstract Number: 2155

Diagnosis of Systemic Sclerosis in the United Kingdom: An Observational Study Using the Clinical Practice Research Datalink

9:00AM-11:00AM: Abstract Number: 2160

Effect of the Metabolic Syndrome on Incident Vascular Events and Mortality in Four Rheumatic Diseases: An 8-Year Longitudinal Analysis

9:00AM-11:00AM: Abstract Number: 2144

Epidemiological Characterisitics of Psoriatric Arthritis: A Nationwide Study of Inpatient Hospitalisations in 2014

9:00AM-11:00AM: Abstract Number: 2142

Exposure to Disease Modifying Antirheumatic Drugs during Pregnancy in Women with Inflammatory Arthritis and the Risk of Serious Maternal Infection: A Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 2161

Hemophagocytic Syndrome in Adults and Association with Rheumatologic Diagnoses: US National Inpatient Trend over Nine Years

9:00AM-11:00AM: Abstract Number: 2135

Identification of Psoriatic Arthritis Using an Administrative Claims-Based Algorithm

9:00AM-11:00AM: Abstract Number: 2164

IMPACT of a Systematic Screening of Multimorbidities in Patients with Chronic Inflammatory Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2167

Incidence and Baseline Characteristics of Exacerbation in Patients with Interstitial Pneumonia with Autoimmune Features: A Single Center Large-Scale Cross-Sectional Cohort Study

9:00AM-11:00AM: Abstract Number: 2145

Increased Risk of Heart Failure with Prolonged Use of Hydroxychloroquine in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2143

Lymphoproliferative Malignancy in Psoriatic Arthritis and the Role of Systemic Immunosuppressive Therapies

9:00AM-11:00AM: Abstract Number: 2134

Modifiable Risk Factors and the Development of Psoriatic Arthritis in People with Psoriasis

9:00AM-11:00AM: Abstract Number: 2136

Mortality Rates and Causes in Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2157

Nationwide Estimated Prevalence of SLE: United States Population-Based Study, 2001-2011

9:00AM-11:00AM: Abstract Number: 2148

Prevalence and Incidence of FMF in Germany – Results of the First Retrospective Analysis of Representative Claims Data

9:00AM-11:00AM: Abstract Number: 2163

Prevalence and Incidence of Idiopathic Inflammatory Myopathies in Korea:a Nationwide Population-Based Study over 10 Years

9:00AM-11:00AM: Abstract Number: 2131

Prevalence of Systemic Lupus Erythematosus (SLE) and Associated Comorbidities in the 2011-2015 Medicare Population

9:00AM-11:00AM: Abstract Number: 2137

Primary Antiphospholipid Syndrome with Vascular Manifestations Is a Rare Disease: A Population-Based, Multi-Source Study Assessing the Prevalence and Incidence in Adults

9:00AM-11:00AM: Abstract Number: 2138

Real-World Evaluation of Treatment Patterns of Methotrexate Users in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2139

Retrospective Study: Association of Hydroxychloroquine Use and Hemolytic Anemia in Patients with Low Levels of Glucose-6-Phosphate Dehydrogenase (G6PD)

9:00AM-11:00AM: Abstract Number: 2168

Seasonal Variation in Incidence of Polymyalgia Rheumatica: A Population-Based

9:00AM-11:00AM: Abstract Number: 2156

Smoking Status Predicts Earlier SLICC Damage Index Progression in a Large SLE Cohort

9:00AM-11:00AM: Abstract Number: 2169

Temporal Trends in Mortality in Patients Hospitalized for Cerebrovascular Events with Psoriatic Arthritis: Data from the Healthcare Cost and Utilization Project from 2010-2014

9:00AM-11:00AM: Abstract Number: 2153

The Effect of Socioeconomic Status on Treatment Outcomes in Lupus Nephritis: Private Versus Public Insurance

9:00AM-11:00AM: Abstract Number: 2151

The Impact of Obesity on SLE Disease Activity

9:00AM-11:00AM: Abstract Number: 2162

The Prevalence, Incidence, and Determinants of Depression and Anxiety in Less Common Systemic Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2165

The Trend of Utilization of Therapeutic Plasmapheresis Among Select Rheumatologic Diseases

9:00AM-11:00AM: Abstract Number: 2166

Treatment of Venous Thrombotic Events in Behçet Disease: A Systematic Literature Review

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].